“Lumpy” licensing lag hits AFT profits

Kiwi pharmaco behind Maxigesic sees net profits down 2/3 year-on-year but leadership remains upbeat about the future Lower licencing income and increased growth in spending were factors which saw the AFT Pharmaceuticals’ first-half net profits down two-thirds year on the same period last year, the company’s annual report shows.   But management remained bullish with

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Interim extension for pharmacist role
Next Chemist Warehouse snares prestige Melbourne site